|
KMID : 1039620180080010073
|
|
Korean Journal of Family Practice
2018 Volume.8 No. 1 p.73 ~ p.79
|
|
|
Lack of Clinical Utility for CYFRA 21-1 in Medical Screening
|
|
Kim Jung-Man
Jeong Hye-Yeong
Km Do-Wi
Lee Soo-Hyoung
Kim Moo-Young
Park Ki-Hyon
|
|
|
Abstract
|
|
|
Background: We analyzed the clinical utility of cytokeratin 19 fragments (CYFRA 21-1) as a biomarker for lung cancer. We evaluated the relationship between CYFRA 21-1 and low-dose chest computed tomography (CT), as well as the various factors affecting CYFRA 21-1 concentration.
Methods: A total of 1,007 Metropolitan officers who underwent medical checkup at the Seoul Medical Center in 2014 were analyzed in this study. To evaluate CYFRA 21-1 as a biomarker, we analyzed the factors affecting its concentration, the correlation between CYFRA 21-1 and low-dose lung CT findings, and the factors affecting CYFRA 21-1 values.
Results: The mean CYFRA 21-1 concentration was 1.74 ng/mL. The sensitivity, specificity, and positive predictive value of CYFRA 21-1 for lung cancer was 0%, 94.4%, and 0%, respectively. Age, sex, smoking history, hypertension, diabetes and hepatitis B infection all affected the prognostic value of CYFRA 21-1. Low-dose chest CT scan was performed in 208/1,007 patients and no correlation was found between CT findings and CYFRA 21-1 concentration. Logistic regression analysis showed that diabetes, other cancers and smoking were independent factors affecting CYFRA 21-1 concentration.
Conclusion: CYFRA 21-1 is not an efficient biomarker for lung cancer. The concentration of CYFRA 21-1 is affected by age, sex, smoking status, blood pressure, diabetes and hepatitis B.
|
|
|
KEYWORD
|
|
|
Tumor Marker, CYFRA 21-1, Medical Screening, Lung Cancer
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|
|